Dr Finger’s expertise is in BARD so I’d expect they need someone to replace her with a broader pharmaceutical background. Maintaining her as a consultant for the BARD antibody test is crucial. I doubt there’s any sinister reasoning behind it.
Ann: Dr Irminger steps down from Board, continues as Consultant, page-9
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.53M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 48.0¢ | 47.0¢ | $5.136K | 10.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23905 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 6204 | 2 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |